Alzheimer's Disease and Parkinson's Disease
Open accessThe DOI matches its Crossref record; 106 of the 107 references it cites were found in a registry or an index.
Abstract
Although most cases of Alzheimer's and Parkinson's disease are sporadic, some cases are clearly familial. This review, part of the Genomic Medicine series, examines the genetics of these familial forms. Although the inherited forms are rare, the knowledge derived from investigating their pathobiology has improved our understanding of the pathobiology of the more common, sporadic forms of the diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general terms, neurodegenerative diseases are thought to be driven by the accumulation of neurotoxic material such as amyloid beta (Aβ) or myelin debris in the central nervous system (CNS) (Nussbaum and Ellis, 2003; Trapp and Nave, 2008).”
From SYK coordinates neuroprotective microglial responses in neurodegenerative disease (2022) · cites this paper as Nussbaum and Ellis, 2003
In the citing paper
“PD pathology is mainly characterized by loss of neurons from the substantia nigra pars compacta in association with the accumulation of ubiquitinated alpha synuclein and other proteins in cytoplasmic inclusions (Lewy bodies) and thread-like proteinaceous inclusions within neurites (Lewy neuritis).”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“However, Lewy bodies are also seen in the cerebral cortex, brainstem nuclei, limbic system, sympathetic ganglia, nucleus basalis of Meinert and myenteric plexus [4].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“This review is focused on the potential of herbal medicine in AD since it is responsible for more than two-thirds of all dementia cases [5,6].”
From Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific Assessment (2020) · cites this paper as [6]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · cited 4×
“Increased Abeta42(43) from cell lines expressing presenilin 1 mutations.”
BackgroundInfluentialSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Self-citationMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Research works printed but not linked: 5
- 10.1001/archinte.151.5.989 · doi:10.1001/archinte.151.5.989 · Paper page
- Clark CM, Ewbank D, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer's disease: neuronal cytoskeletal abnormalities. In: Growdon JH, Rossor MN, eds. The dementias. Vol. 19 of Blue books of practical neurology. Boston: Butterworth–Heinemann, 1998:285-304.
- Duvoisin RC, 1996, Adv Neurol, 69, 33
- Louis ED, 1996, Adv Neurol, 69, 311
- Matsumine H, 1997, Am J Hum Genet, 60, 588
Cited by
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310
Molecular Mechanisms of Amyloidosis
Merlini, G., & Bellotti, V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023144 · Cited by 1,920
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281
Simard, A. R., Soulet, D., Gowing, G., Julien, J.-P., & Rivest, S. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.022 · Cited by 1,265
Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
Erkkinen, M. G., Kim, M.-O., & Geschwind, M. D. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,124
A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci
Chang, D., Nalls, M. A., Hallgrímsdóttir, I. B., Hunkapiller, J., van der Brug, M., Cai, F., International Parkinson's Disease Genomics Consortium, 23andMe Research Team, Kerchner, G. A., Ayalon, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3955 · Cited by 1,112
Neurodegenerative diseases and oxidative stress
Emerit, J., Edeas, M., & Bricaire, F. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2003.11.004 · Cited by 1,031
Review Article: Genetics of Alzheimer Disease
Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383571 · Cited by 1,029
Structure and Dynamics of Micelle-bound Human α-Synuclein
Ulmer, T. S., Bax, A., Cole, N. B., & Nussbaum, R. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411805200 · Cited by 966
Self-citationAgeing and Parkinson's disease: Why is advancing age the biggest risk factor?
Reeve, A., Simcox, E., & Turnbull, D. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.004 · Cited by 947
Polyphenols and Human Health: Prevention of Disease and Mechanisms of Action
Vauzour, D., Rodriguez-Mateos, A., Corona, G., Oruna-Concha, M. J., & Spencer, J. P. E. (2010) · Nutrients · doi:10.3390/nu2111106 · Cited by 855
A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines
Rubio-Perez, J. M., & Morillas-Ruiz, J. M. (2012) · The Scientific World Journal · doi:10.1100/2012/756357 · Cited by 839
Buendia, I., Michalska, P., Navarro, E., Gameiro, I., Egea, J., & León, R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.003 · Cited by 678
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
“The common clinical hallmark of AD is the extracellular deposition of amyloid beta (Aβ) peptide along with phosphorylated tau protein, which leads to irreversible neuronal loss and thereby to loss of memory and decision-making power.(95,96) Furthermore, the degeneration of dopaminergic neurons of the brain followed by…”
BackgroundWhat Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 611
The Epidemiology of the Comorbidity of Epilepsy in the General Population
Gaitatzis, A., Carroll, K., Majeed, A., & Sander, J. W. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.17504.x · Cited by 603
Rodriguez-Mateos, A., Vauzour, D., Krueger, C. G., Shanmuganayagam, D., Reed, J., Calani, L., Mena, P., Del Rio, D., & Crozier, A. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1330-7 · Cited by 602
Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Choi, J., Levey, A. I., Weintraub, S. T., Rees, H. D., Gearing, M., Chin, L.-S., & Li, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314124200 · Cited by 568
Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases
Irvine, G. B., El-Agnaf, O. M., Shankar, G. M., & Walsh, D. M. (2008) · Molecular Medicine · doi:10.2119/2007-00100.irvine · Cited by 550
Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis
John van Geest Centre for Brain Repair, D. O. C. N., Kouli, A., Torsney, K. M., Department of Medicine for the Elderly, C. U. H. N. F. T., Clinical Gerontology Unit, D. O. P. H. A. P. C., Kuan, W.-L., & John van Geest Centre for Brain Repair, D. O. C. N. (2018) · Parkinson’s Disease: Pathogenesis and Clinical Aspects · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch1 · Cited by 507
Nonlinear dynamics of multi-omics profiles during human aging
Shen, X., Wang, C., Zhou, X., Zhou, W., Hornburg, D., Wu, S., & Snyder, M. P. (2024) · Nature Aging · doi:10.1038/s43587-024-00692-2 · Cited by 500
Alzheimer's disease: synaptic dysfunction and Aβ
Shankar, G. M., & Walsh, D. M. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-48 · Cited by 486
Luteolin as an anti-inflammatory and neuroprotective agent: A brief review
Nabavi, S. F., Braidy, N., Gortzi, O., Sobarzo-Sanchez, E., Daglia, M., Skalicka-Woźniak, K., & Nabavi, S. M. (2015) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2015.09.002 · Cited by 480
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
“However, Lewy bodies are also seen in the cerebral cortex, brainstem nuclei, limbic system, sympathetic ganglia, nucleus basalis of Meinert and myenteric plexus [4].”
BackgroundPang, S. Y.-Y., Ho, P. W.-L., Liu, H.-F., Leung, C.-T., Li, L., Chang, E. E. S., Ramsden, D. B., & Ho, S.-L. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0165-9 · Cited by 427
The retina in Parkinson's disease
Archibald, N. K., Clarke, M. P., Mosimann, U. P., & Burn, D. J. (2009) · Brain · doi:10.1093/brain/awp068 · Cited by 408
Olivares, D., K. Deshpande, V., Shi, Y., K. Lahiri, D., H. Greig, N., T. Rogers, J., & Huang, X. (2012) · Current Alzheimer Research · doi:10.2174/156720512801322564 · Cited by 407
Gaucher disease: complexity in a “simple” disorder
Sidransky, E. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.08.015 · Cited by 399
“[69] R.”
ResultGoldman, J. S., Hahn, S. E., Catania, J. W., Larusse-Eckert, S., Butson, M. B., Rumbaugh, M., Strecker, M. N., Roberts, J. S., Burke, W., Mayeux, R., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e31821d69b8 · Cited by 393
Glucocerebrosidase mutations in subjects with parkinsonism
Lwin, A. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.11.004 · Cited by 371
Epidemiology of Parkinson Disease
Lee, A., & Gilbert, R. M. (2016) · Neurologic Clinics · doi:10.1016/j.ncl.2016.06.012 · Cited by 366
Risk Factors for Vascular Dementia and Alzheimer Disease
Gorelick, P. B. (2004) · Stroke · doi:10.1161/01.str.0000143318.70292.47 · Cited by 365
Therapeutic approaches to Alzheimer's disease
Klafki, H.-W., Staufenbiel, M., Kornhuber, J., & Wiltfang, J. (2006) · Brain · doi:10.1093/brain/awl280 · Cited by 362
Incidence of parkinsonism and Parkinson disease in a general population: The Rotterdam Study
de Lau, L. M. L., Giesbergen, P. C. L. M., de Rijk, M. C., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2004) · Neurology · doi:10.1212/01.wnl.0000140706.52798.be · Cited by 360
Genes and the parsing of cognitive processes
Goldberg, T. E., & Weinberger, D. R. (2004) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2004.05.011 · Cited by 356
Genetic aspects of Alzheimer disease.
Bird, T. D. (2008) · Genetics in Medicine · doi:10.1097/gim.0b013e31816b64dc · Cited by 356
Hilton, D., Stephens, M., Kirk, L., Edwards, P., Potter, R., Zajicek, J., Broughton, E., Hagan, H., & Carroll, C. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1214-6 · Cited by 345
“Parkinson’s disease is one of the most common neurodegenerative disorders affecting the ageing population across the world [11, 31].”
BackgroundIn vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe
Hintersteiner, M., Enz, A., Frey, P., Jaton, A.-L., Kinzy, W., Kneuer, R., Neumann, U., Rudin, M., Staufenbiel, M., Stoeckli, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1085 · Cited by 341
Pyroptosis in health and disease: mechanisms, regulation and clinical perspective
Liu, Y., Pan, R., Ouyang, Y., Gu, W., Xiao, T., Yang, H., Tang, L., Wang, H., Xiang, B., & Chen, P. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01958-2 · Cited by 337
Scott, L. E., & Orvig, C. (2009) · Chemical Reviews · doi:10.1021/cr9000176 · Cited by 332
Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
Fields, C. R., Bengoa-Vergniory, N., & Wade-Martins, R. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00299 · Cited by 328
“5–1% among individuals 65–69 years of age, rising to 1–3% among persons 80 years of age and older (Nussbaum and Ellis, 2003).”
BackgroundSystemic markers of inflammation and cognitive decline in old age
Schram, M. T., Euser, S. M., De Craen, A. J. M., Witteman, J. C., Frölich, M., Hofman, A., Jolles, J., Breteler, M. M. B., & Westendorp, R. G. J. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01159.x · Cited by 326
Chen, H.-X., Liang, F.-C., Gu, P., Xu, B.-L., Xu, H.-J., Wang, W.-T., Hou, J.-Y., Xie, D.-X., Chai, X.-Q., & An, S.-J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2473-5 · Cited by 319
α‐Synuclein and Parkinson's disease
Recchia, A., Debetto, P., Negro, A., Guidolin, D., Skaper, S. D., & Giusti, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0338rev · Cited by 318
S-Glutathionylation: From Molecular Mechanisms to Health Outcomes
Xiong, Y., Uys, J. D., Tew, K. D., & Townsend, D. M. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3540 · Cited by 314
Sleep Disturbance, Cognitive Decline, and Dementia: A Review
Wu, M., Rosenberg, P., Spira, A., & Wennberg, A. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1604351 · Cited by 309
The hallmarks of Parkinson's disease
Antony, P. M. A., Diederich, N. J., Krüger, R., & Balling, R. (2013) · The FEBS Journal · doi:10.1111/febs.12335 · Cited by 300
Zhu, J., Cui, Y., Zhang, J., Yan, R., Su, D., Zhao, D., Wang, A., & Feng, T. (2024) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(24)00094-1 · Cited by 299
SYK coordinates neuroprotective microglial responses in neurodegenerative disease
Ennerfelt, H., Frost, E. L., Shapiro, D. A., Holliday, C., Zengeler, K. E., Voithofer, G., Bolte, A. C., Lammert, C. R., Kulas, J. A., Ulland, T. K., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.030 · Cited by 297
“Though the ability of SYK to modulate Aβ and tau biology has been explored in previous in vitro studies using immortalized CNS lines and pharmacological agents with well-described off-target effects (Lawlor et al., 2018; Paris et al., 2014), the extent to which SYK influences in vivo microglial responses and neurodege…”
InfluentialThe influence of microglia on the pathogenesis of Parkinson's disease
Long-Smith, C. M., Sullivan, A. M., & Nolan, Y. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.08.001 · Cited by 296
Ganguly, G., Chakrabarti, S., Chatterjee, U., & Saso, L. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s130514 · Cited by 294
Testicular Cancer Survivorship: Research Strategies and Recommendations
Travis, L. B., Beard, C., Allan, J. M., Dahl, A. A., Feldman, D. R., Oldenburg, J., Daugaard, G., Kelly, J. L., Dolan, M. E., Hannigan, R., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq216 · Cited by 294
Virus-like particle vaccinology, from bench to bedside
Mohsen, M. O., & Bachmann, M. F. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00897-8 · Cited by 289
Kuo, Y.-M., Li, Z., Jiao, Y., Gaborit, N., Pani, A. K., Orrison, B. M., Bruneau, B. G., Giasson, B. I., Smeyne, R. J., Gershon, M. D., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq038 · Cited by 286
Self-citationCellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
“PD is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, the presence of cytoplasmic protein aggregates, known as Lewy bodies, that contain a variety of proteins, including ubiquitin and α-synuclein (Nussbaum and Ellis, 2003; Thomas and Beal, 2011).”
BackgroundNeuroprotective and Anti-Aging Potentials of Essential Oils from Aromatic and Medicinal Plants
Ayaz, M., Sadiq, A., Junaid, M., Ullah, F., Subhan, F., & Ahmed, J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00168 · Cited by 281
“…disorders, characterized by cognitive dysfunctions, behavioral turbulence, gradual memory loss, scarcity in cholinergic neurotransmission, oxidative stress, accumulation of amyloid plaques (amyloid-β, Aβ) and neurofibrillary tangles (NFTs) in the brain areas (Nussbaum and Ellis, 2003).”
BackgroundPesticide exposure and risk of Alzheimer’s disease: a systematic review and meta-analysis
Yan, D., Zhang, Y., Liu, L., & Yan, H. (2016) · Scientific Reports · doi:10.1038/srep32222 · Cited by 231
Depression in neurodegenerative diseases: Common mechanisms and current treatment options
Galts, C. P. C., Bettio, L. E. B., Jewett, D. C., Yang, C. C., Brocardo, P. S., Rodrigues, A. L. S., Thacker, J. S., & Gil-Mohapel, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.002 · Cited by 269
Autosomal Recessive Causes Likely in Early-Onset Alzheimer Disease
Wingo, T. S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.221 · Cited by 265
“The concordance pattern among all AD and LOAD was higher when the affected proband (offspring) was male and the relative (parent) was female, which is the expected pattern of inheritance if LOAD is a polygenic disease and AD is more prevalent in women than men.(11) No such pattern was seen for EOAD, suggesting it is n…”
BackgroundGuttmacher, A. E., & Collins, F. S. (2003) · New England Journal of Medicine · doi:10.1056/nejme038132 · Cited by 262
Aging of the Respiratory System: Impact on Pulmonary Function Tests and Adaptation to Exertion
Janssens, J.-P. (2005) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2005.05.004 · Cited by 262
“Indeed, prevalence of dementia increases with aging, reaching 5.6% after age 75, 22% after age 80, and 30% as of age 90 [ 50 ].”
BackgroundInfluentialThe centrosome in human genetic disease
Badano, J. L., Teslovich, T. M., & Katsanis, N. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1557 · Cited by 251
Rosenkranz, D., Weyer, S., Tolosa, E., Gaenslen, A., Berg, D., Leyhe, T., Gasser, T., & Stoltze, L. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.05.011 · Cited by 254
“Genetic risk factors have been discovered for both diseases but these account currently for less then 10% of all cases (Nussbaum and Ellis, 2003).”
BackgroundGenomic Priorities and Public Health
Merikangas, K. R., & Risch, N. (2003) · Science · doi:10.1126/science.1091468 · Cited by 250
First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers
Schenk, D. B., Koller, M., Ness, D. K., Griffith, S. G., Grundman, M., Zago, W., Soto, J., Atiee, G., Ostrowitzki, S., & Kinney, G. G. (2017) · Movement Disorders · doi:10.1002/mds.26878 · Cited by 252
“Parkinson’s disease affects 7 to 10 million persons worldwide,(3) making it the second most prevalent neurodegenerative disorder after Alzheimer’s disease.(4) Parkinson’s disease is also associated with significant economic burden; in 2010, in the United States, medical expenses related to Parkinson’s disease were app…”
BackgroundGlucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease
Taguchi, Y. V., Liu, J., Ruan, J., Pacheco, J., Zhang, X., Abbasi, J., Keutzer, J., Mistry, P. K., & Chandra, S. S. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1525-17.2017 · Cited by 243
The economic impact of Parkinson's disease
Findley, L. J. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.06.003 · Cited by 247
“It is the second most common neurodegenerative disorder after Alzheimer’s disease [1] and is a major and increasing burden on patients, families, carers and on healthcare systems [2].”
BackgroundGenetics of Alzheimer's Disease: A Centennial Review
Ertekin-Taner, N. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.009 · Cited by 234
Parkinson’s Disease: A Review from Pathophysiology to Treatment
Marino, B. L. B., de Souza, L. R., Sousa, K. P. A., Ferreira, J. V., Padilha, E. C., da Silva, C. H. T. P., Taft, C. A., & Hage-Melim, L. I. S. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557519666191104110908 · Cited by 226
Intrinsic disorder in proteins associated with neurodegenerative diseases
Uversky, V. (2009) · Frontiers in Bioscience · doi:10.2741/3594 · Cited by 233
“The clinical hallmarks are progressive impairment in memory, judgment, decision making, orientation to physical surroundings, and language [82].”
BackgroundEpidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Jiang, T., Yu, J.-T., Tian, Y., & Tan, L. (2013) · Current Alzheimer Research · doi:10.2174/15672050113109990155 · Cited by 225
Agrawal, M., Saraf, S., Saraf, S., Dubey, S. K., Puri, A., Patel, R. J., Ajazuddin, Ravichandiran, V., Murty, U. S., & Alexander, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.020 · Cited by 230
The association between Mediterranean diet adherence and Parkinson's disease
Alcalay, R. N., Gu, Y., Mejia‐Santana, H., Cote, L., Marder, K. S., & Scarmeas, N. (2012) · Movement Disorders · doi:10.1002/mds.24918 · Cited by 228
Neuroprotective Potential of Limonene and Limonene Containing Natural Products
Eddin, L. B., Jha, N. K., Meeran, M. F. N., Kesari, K. K., Beiram, R., & Ojha, S. (2021) · Molecules · doi:10.3390/molecules26154535 · Cited by 199
Parkinson Disease: Diagnostic Utility of Diffusion Kurtosis Imaging
Wang, J.-J., Lin, W.-Y., Lu, C.-S., Weng, Y.-H., Ng, S.-H., Wang, C.-H., Liu, H.-L., Hsieh, R.-H., Wan, Y.-L., & Wai, Y.-Y. (2011) · Radiology · doi:10.1148/radiol.11102277 · Cited by 226
Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson???s Disease
Jankovic, J., & Stacy, M. (2007) · CNS Drugs · doi:10.2165/00023210-200721080-00005 · Cited by 213
Camps, J., Samà, A., Martín, M., Rodríguez-Martín, D., Pérez-López, C., Moreno Arostegui, J. M., Cabestany, J., Català, A., Alcaine, S., Mestre, B., et al. (2018) · Knowledge-Based Systems · doi:10.1016/j.knosys.2017.10.017 · Cited by 224
The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration
Cummings, J. L., Henchcliffe, C., Schaier, S., Simuni, T., Waxman, A., & Kemp, P. (2011) · Brain · doi:10.1093/brain/awr177 · Cited by 213
The genetic landscape of Parkinson's disease
Lunati, A., Lesage, S., & Brice, A. (2018) · Revue Neurologique · doi:10.1016/j.neurol.2018.08.004 · Cited by 215
Contributions of non-human primates to neuroscience research
Capitanio, J. P., & Emborg, M. E. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60489-4 · Cited by 213
Toward a Biopsychosocial Model for 21st‐Century Genetics
Rolland, J. S., & Williams, J. K. (2005) · Family Process · doi:10.1111/j.1545-5300.2005.00039.x · Cited by 211
Gap junctions and neurological disorders of the central nervous system
Nakase, T., & Naus, C. C. G. (2004) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2004.01.009 · Cited by 205
Gender differences in dementia risk factors
Azad, N. A., Al Bugami, M., & Loy-English, I. (2007) · Gender Medicine · doi:10.1016/s1550-8579(07)80026-x · Cited by 204
The Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies
Perez-Pardo, P., Kliest, T., Dodiya, H. B., Broersen, L. M., Garssen, J., Keshavarzian, A., & Kraneveld, A. D. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.042 · Cited by 203
“It has a prevalence of 0.3% in the general population and 1–3% in the population over the age of 65 (de Rijk et al., 2000; Nussbaum and Ellis, 2003).”
BackgroundInfluentialThe Gut–Brain Axis and Its Relation to Parkinson’s Disease: A Review
Klann, E. M., Dissanayake, U., Gurrala, A., Farrer, M., Shukla, A. W., Ramirez-Zamora, A., Mai, V., & Vedam-Mai, V. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.782082 · Cited by 182
“Keywords: Parkinson’s disease, gut–brain axis, microbiome, alpha-synuclein, dysbiosis INTRODUCTION Parkinson’s disease (PD) is the second most common neurodegenerative disorder with an estimated prevalence of approximately 1% among individuals over the age of 65 (Nussbaum, 2003).”
BackgroundLipid-based nanoparticles with high binding affinity for amyloid-β1–42 peptide
Gobbi, M., Re, F., Canovi, M., Beeg, M., Gregori, M., Sesana, S., Sonnino, S., Brogioli, D., Musicanti, C., Gasco, P., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.04.044 · Cited by 192
Ramanan, V. K., & Saykin, A. J. (2013) · Europe PMC (PubMed Central) · Cited by 259
MPTP and MPP+ target specific aminergic cell populations in larval zebrafish
Sallinen, V, Torkko, V, Sundvik, M., Reenilä, I., Khrustalyov, D., Kaslin, J., & Panula, P. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05793.x · Cited by 190
“Parkinson’s disease (PD) is a progressive and common neurodegenerative disease, affecting over 1% of the population aged over 60 years (Nussbaum and Ellis 2003).”
BackgroundMemory loss in Alzheimer’s disease: implications for development of therapeutics
Gold, C. A., & Budson, A. E. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.12.1879 · Cited by 170
Amyloidogenesis of Natively Unfolded Proteins
Uversky, V. (2008) · Current Alzheimer Research · doi:10.2174/156720508784533312 · Cited by 188
Epidemiology of neurological diseases in older adults
Dumurgier, J., & Tzourio, C. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2020.01.356 · Cited by 167
Mutations of Presenilin Genes in Dilated Cardiomyopathy and Heart Failure
Li, D., Parks, S. B., Kushner, J. D., Nauman, D., Burgess, D., Ludwigsen, S., Partain, J., Nixon, R. R., Allen, C. N., Irwin, R. P., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/509900 · Cited by 182
Eckert, A., Schmitt, K., & Götz, J. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt74 · Cited by 177
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
Cole, T. A., Zhao, H., Collier, T. J., Sandoval, I., Sortwell, C. E., Steece-Collier, K., Daley, B. F., Booms, A., Lipton, J., Welch, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.135633 · Cited by 151
The sodium leak channel, NALCN, in health and disease
Cochet-Bissuel, M., Lory, P., & Monteil, A. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00132 · Cited by 172
Metadata
- Authors
- Nussbaum, R. L., & Ellis, C. E.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Nussbaum, Robert L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1356-1364
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149522871
- Cited by
- 1,351
- References
- 107
- Citations by year
- 2026: 25 · 2025: 55 · 2024: 75 · 2023: 74 · 2022: 80 · 2021: 82 · 2020: 80 · 2019: 83 · 2018: 74 · 2017: 74 · 2016: 63 · 2015: 54 · 2014: 65 · 2013: 46 · 2012: 66
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, Parkinson's disease, genetic susceptibility, inherited neurodegenerative disorders
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Apolipoproteins E, Humans, Molecular Sequence Data, Nerve Tissue Proteins, Substantia Nigra, Prevalence, Amyloid beta-Protein Precursor, Lewy Bodies, Mutation, Missense, Parkinsonian Disorders, Synucleins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.